Analytes/procedures in bold
type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS).
Program FL8 is intended for laboratories that currently or will begin to perform minimal residual disease (MRD) testing (rare event analysis) for mature B‑cell leukemia/lymphoma.
- Two 1.1‑mL specimens containing a cell line/whole blood mixture simulating mature B‑cell leukemia/lymphoma minimal residual disease with clinical history and pertinent laboratory data
- One online case with clinical history and gated dot plots
This program has stability of two days or less. The CAP cannot guarantee performance or offer credits for orders placed for shipment outside of the US and Canada.
- Shipment A: February 8
- Shipment B: August 2